Clinical implications of cefoperazone–sulbactam MIC values in Pseudomonas aeruginosa bloodstream infections: a multicentre study
JAC-Antimicrobial Resistance · 30.04.2026 · 8 (3)
DOI: 10.1093/jacamr/dlag073 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAC-Antimicrobial Resistance, online erschienen am 11.05.2026. Verfasst von Shian-Sen Shie und 13 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, Department of Internal Medicine, Chang Gung Memorial Hospital, Taoyuan, Taiwan. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Cefoperazone/sulbactam (CPZ/SUL, 1:1) is used for Pseudomonas aeruginosa bloodstream infections (BSIs); however, its clinical minimum inhibitory concentration (MIC) breakpoint remains undefined. This study aimed to evaluate the association between CPZ/SUL MIC values and clinical outcomes.
Methods
We retrospectively analysed 122 adults with P. aeruginosa BSIs treated with CPZ/SUL (1:1) for ≥3 days across eight Taiwanese medical centres (July 2017−May 2024). MICs were determined using agar dilution, and outcomes were categorized as favourable (cure/improvement) or poor (failure/mortality). Isolate susceptibilities to other agents were also evaluated.
Results
Overall, 76.2% achieved favourable outcomes. Patients with MICs ≤16 mg/L had significantly higher favourable rates than those with MICs ≥32 mg/L (81.0% versus 54.5%; P = 0.013). This association remained significant across all hierarchical models, including the fully adjusted model (aOR 2.74, 95% CI 1.44–5.25). Pneumonia-associated BSIs had lower favourable outcomes (64.1%). Among all isolates, 82% exhibited MICs ≤16 mg/L. Carbapenem-resistant P. aeruginosa (CRPA) accounted for 18% of cases, with 59.1% showing favourable responses to CPZ/SUL.
Conclusions
Lower CPZ/SUL MIC values were independently associated with more favourable clinical outcomes in patients with P. aeruginosa BSIs. These findings support the clinical relevance of MIC stratification and may inform antimicrobial stewardship and individualized treatment decisions.
Autor:innen und Institutionen
- Division of Infectious Diseases, Department of Internal Medicine, Chang Gung Memorial Hospital, Taoyuan, Taiwan.
- Division of Infectious Diseases and Tropical Medicine, Department of Internal Medicine, Tri- Service General Hospital, National Defense Medical Center, Taipei, Taiwan.
- Institute of Preventive Medicine, National Defense Medical Center, Taipei, Taiwan.
- Division of Infectious Diseases, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan.
- Division of Infectious Diseases, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.
- Center for Liquid Biopsy and Cohort Research, Kaohsiung Medical University, Kaohsiung, Taiwan.
ORCID-Profile: Shian-Sen Shie, Ting-Shu Wu
Zitieren
APA
Shie, S. S., Wu, T. S., Chang, F. Y., Yang, Y. S., Chiang, T. T., Ho, M. W., Chou, C. H., Lu, P. L., Lin, S. Y., Wang, F. D., Tang, H. J., Shi, Z. Y., Chuang, Y. C., & Liu, J. W. (2026). Clinical implications of cefoperazone–sulbactam MIC values in Pseudomonas aeruginosa bloodstream infections: a multicentre study. JAC-Antimicrobial Resistance, 8(3). https://doi.org/10.1093/jacamr/dlag073
Vancouver
Shie SS, Wu TS, Chang FY, Yang YS, Chiang TT, Ho MW, et al. Clinical implications of cefoperazone–sulbactam MIC values in Pseudomonas aeruginosa bloodstream infections: a multicentre study. JAC-Antimicrobial Resistance. 2026;8(3). doi:10.1093/jacamr/dlag073
BibTeX
@article{Shie2026,
author = {Shie, Shian-Sen and Wu, Ting-Shu and Chang, Feng-Yee and Yang, Ya-Sung and Chiang, Tsung-Ta and Ho, Mao-Wang and Chou, Chia-Hui and Lu, Po-Liang and Lin, Shang-Yi and Wang, Fu-Der and Tang, Hung-Jen and Shi, Zhi-Yuan and Chuang, Yin-Ching and Liu, Jien-Wei},
title = {Clinical implications of cefoperazone–sulbactam MIC values in Pseudomonas aeruginosa bloodstream infections: a multicentre study},
journal = {JAC-Antimicrobial Resistance},
year = {2026},
volume = {8},
number = {3},
doi = {10.1093/jacamr/dlag073}
}
EUVIMED